CVM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Stats
今日成交量	133 298
平均成交量	302 678
市值	79.89M
EPS	$0 ( 2024-02-13 )
下一个收益日期	( $-0.140 ) 2024-05-10
Last Dividend	$0.250 ( 1996-08-28 )
Next Dividend	$0 ( N/A )
P/E	-2.14
ATR14	$0.00600 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Gobbo Mario	Sell	0	Common Stock
2024-04-19	Gobbo Mario	Sell	64 000	Options
2024-04-19	Watson Robert Eugene	Buy	64 000	Options
2024-04-19	Baillavoine Bruno Jean-marie	Buy	64 000	Options
2024-04-19	Talor Eyal	Buy	182 000	Options

INSIDER POWER
90.70
Last 100 transactions
Buy: 5 618 116 \| Sell: 153 000

音量相关性

長: 0.30 (neutral)

短: 0.47 (neutral)

Signal:(59.008) Neutral

CEL-SCI Corp 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CEL-SCI Corp 相关性 - 货币/商品

0.54
( weak )

0.85
( strong )

0.00
( neutral )

0.46
( neutral )

0.40
( neutral )

-0.74
( moderate negative )

CEL-SCI Corp 财务报表

Annual	2023
营收:	$0
毛利润:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2023
营收:	$0
毛利润:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2022
营收:	$0
毛利润:	$-3.88M (0.00 %)
EPS:	$-0.890

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.900

Financial Reports:

No articles found.

CEL-SCI Corp Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

CEL-SCI Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	1996-08-28
Last Dividend	$0.250	1996-08-28
Next Dividend	$0	N/A
Payout Date	2017-06-15
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
LCTU	Ex Dividend Junior	2023-06-07	Quarterly	0.00%
SEB	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
AVSU	Ex Dividend Junior	2023-09-21	Quarterly	0.00%
EPM	Ex Dividend Knight	2023-09-21	Quarterly	0.00%
IMO	Ex Dividend King	2023-08-31	Quarterly	0.00%
PTRB	Ex Dividend Junior	2023-08-01	Monthly	0.00%
DHY	Ex Dividend King	2023-09-18	Monthly	0.00%
GROY	Ex Dividend Junior	2023-06-16	Quarterly	0.00%
PCG-PA	Ex Dividend Junior	2023-07-28	Annually	0.00%
CRF	Ex Dividend Knight	2023-10-13	Monthly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.087	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.264	0.800	8.68	6.94	[1 - 3]
quickRatioTTM	0.184	0.800	-3.62	-2.90	[0.8 - 2.5]
cashRatioTTM	0.666	1.500	7.41	10.00	[0.2 - 2]
debtRatioTTM	0.456	-1.500	2.40	-3.59	[0 - 0.6]
interestCoverageTTM	-42.08	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
freeCashFlowPerShareTTM	-0.484	2.00	-0.242	-0.484	[0 - 20]
debtEquityRatioTTM	1.035	-1.500	5.86	-8.79	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.761	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.30	1.000	-0.333	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.484	2.00	-0.161	-0.484	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0459	1.500	-3.64	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.893

CEL-SCI Corp

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.